2832 Induction chemotherapy with docetaxel, cisplatin and fluorouracil in locally advanced oral cavity cancer
Josué Pereira, Joaquim Abreu de Sousa(IPO Porto), Ana Filipa Ferreira, M. Lima, Joäo Antônio Matheus Guimaräes, José Dinis(Instituto Português de Oncologia Francisco Gentil), D. Brito, Daniel Ferreira da Cunha, Pedro Martins(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ana Mesquita, César Erineudo Tavares de Araújo, Cecília Cacau de Sousa Ribeiro, Aurélie Moreira, C. Sanches, R. Capelo, Anabela Faria de Sousa
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87